Evidence map›Paper›PMID 39112453›Full record

ArticleBlood cancer journal2024

Identification of genetic subtypes in follicular lymphoma.

Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y He and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Victoria SheltonPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Rajesh DetrojaPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Ting LiuPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8775-5507
Keren IsaevPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Anjali SilvaPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Verena PasseriniDepartment of Internal Medicine III, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.
Mehran BakhtiariPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Lourdes CalventePrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Michael HongPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Michael Y HePrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.ORCID 0000-0002-2235-2758
Saloni ModiPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Samantha A HershenfeldPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Maja LudvigsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-5089-3271
Charlotte MadsenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Stephen Hamilton-DutoitDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Francesco Annibale d'AmoreDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Marianne BrodtkorbDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Nathalie A JohnsonJewish General Hospital, Montreal, QC, Canada.
Tara BaetzDepartment of Oncology, Queen's University, Kingston, ON, Canada.
David LeBrunDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
Josh W D TobinMater Research University of Queensland, Brisbane, QLD, Australia.
Maher K GandhiMater Research University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-1000-5393
Andrew J MungallCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Susana Ben-NeriahBC Cancer, Vancouver, BC, Canada.
Christian SteidlBC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9842-9750
Jan DelabieLaboratory and Medicine Program, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-5023-0689
Rosemarie Tremblay-LeMayLaboratory and Medicine Program, University Health Network, Toronto, ON, Canada.
Opeyemi JegedeDana Farber Cancer Institute, Boston, MA, USA.
Oliver WeigertDepartment of Internal Medicine III, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.ORCID 0000-0002-0987-7373
Brad KahlWashington University, St. Louis, MO, USA.ORCID 0000-0003-0459-6609
Andrew M EvensRutgers Cancer Institute, New Brunswick, NJ, USA.
Robert KridelPrincess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada. robert.kridel@uhn.ca.ORCID 0000-0003-0287-7124

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
Deutsche Forschungsgemeinschaft (German Research Foundation) WE 4679/2Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation) 2021_EKES.13Leukemia and Lymphoma Society (Leukemia & Lymphoma Society) 6599-20Leukemia and Lymphoma Society of Canada (Leukemia & Lymphoma Society of Canada) 513421NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA233339Terry Fox Research Institute (Institut de Recherche Terry Fox) 1079
6 · The paper itself

Abstract

Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies.

Indexed as

Lymphoma, FollicularAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedMutationPrognosisBiomarkers, Tumor

Identifiers

PMID39112453
PMCPMC11306633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.